Targeting a diverse spectrum of cancers.

Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.

Platform

Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.

Investors

DCPH

$22.88

-0.26
04/24/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.

Latest News

Apr
17
2018
Preclinical Data Demonstrate That Deciphera Pharmaceuticals' DCC-2618 Exhibits Broader Inhibition Profile Against Primary and Secondary Drug-Resistant Mutations in Gastrointestinal Stromal Tumors (GIST) Compared to Approved and Investigational Agents Read More »
Apr
16
2018
Deciphera Pharmaceuticals, Inc. Reports Updated Data from Ongoing Phase 1 Clinical Trial of DCC-2618 at 2018 American Association for Cancer Research (AACR) Annual Meeting Read More »
Mar
28
2018
Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter 2017 Financial Results and Corporate Highlights Read More »